Guangzhi Ma1, Yunfu Deng1, Hai Jiang2, Wen Li1, Qiang Wu1, Qinghua Zhou3. 1. Lung Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China. 2. Department of Orthopedic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China. 3. Lung Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China. Electronic address: zhouqh135@163.com.
Abstract
BACKGROUND: Programmed cell death-ligand 1 (PD-L1) seemed to be associated with the outcomes of non-small cell lung cancer. However the prognostic role of PD-L1 expression among NSCLC remained unclear and inconsistent. The aim of the study set out to evaluate the correlation between PD-L1 expression and the prognosis of patients that developed NSCLC. METHODS: Identified literatures were extracted of various electronic databases and a meta-analysis was performed to evaluate the prognostic role of PD-L1 among NSCLC patients. RESULTS: Totally 25 studies from 11 countries containing 5861 patients were included in the meta-analysis. The pooled hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) were 1.176 (95% CI: 1.016-1.361, P = 0.029) and 1.170 (95% CI: 0.984-1.392, P = 0.076), respectively. High PD-L1 expression on NSCLC tissue was also related with worse OS among Asian patients (HR = 1.381, 95% CI: 1.127-1.629, P = 0.002), adenocarcinomas (HR = 1.899, 95% CI: 1.306-2.762, P = 0.001) and poor PFS in non-Asian patients (HR = 1.695, 95% CI: 1.158-2.480, P = 0.002). Sensitivity analysis indicated that removal of any particular included literature won't affect the pooled results. Publication bias among the studies was not significant neither. CONCLUSIONS: PD-L1 expression is a prognostic factor related with poor survival among patients that developed NSCLC.
BACKGROUND:Programmed cell death-ligand 1 (PD-L1) seemed to be associated with the outcomes of non-small cell lung cancer. However the prognostic role of PD-L1 expression among NSCLC remained unclear and inconsistent. The aim of the study set out to evaluate the correlation between PD-L1 expression and the prognosis of patients that developed NSCLC. METHODS: Identified literatures were extracted of various electronic databases and a meta-analysis was performed to evaluate the prognostic role of PD-L1 among NSCLCpatients. RESULTS: Totally 25 studies from 11 countries containing 5861 patients were included in the meta-analysis. The pooled hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) were 1.176 (95% CI: 1.016-1.361, P = 0.029) and 1.170 (95% CI: 0.984-1.392, P = 0.076), respectively. High PD-L1 expression on NSCLC tissue was also related with worse OS among Asian patients (HR = 1.381, 95% CI: 1.127-1.629, P = 0.002), adenocarcinomas (HR = 1.899, 95% CI: 1.306-2.762, P = 0.001) and poor PFS in non-Asian patients (HR = 1.695, 95% CI: 1.158-2.480, P = 0.002). Sensitivity analysis indicated that removal of any particular included literature won't affect the pooled results. Publication bias among the studies was not significant neither. CONCLUSIONS:PD-L1 expression is a prognostic factor related with poor survival among patients that developed NSCLC.
Authors: Jing-Jing Wang; Michelle K Siu; Yu-Xin Jiang; Thomas H Leung; David W Chan; Ran-Ran Cheng; Annie N Cheung; Hextan Y Ngan; Karen K Chan Journal: Oncoimmunology Date: 2019-09-05 Impact factor: 8.110
Authors: Giuseppe Troiano; Vito C A Caponio; Khrystyna Zhurakivska; Claudia Arena; Giuseppe Pannone; Marco Mascitti; Andrea Santarelli; Lorenzo Lo Muzio Journal: Cell Prolif Date: 2018-11-15 Impact factor: 6.831